uploads/2018/06/Chart-06-2-1.jpg

Which Pfizer Products Are Seeing Lower Sales

By

Updated

Products with declining sales

Pfizer’s (PFE) portfolio also includes some products that are losing market share due to competition from other products in the market. These products include Enbrel (outside the United States and Canada), BeneFix, Prevnar 13, Toviaz, Inylta, EpiPen, Premarin, Precedex, Tygacil, Vfend, Lyrica, Celebrex, Revatio, Pristiq, Zyvox, and Viagra. The chart below outlines some of these products’ revenue.

Revenue by product in Q1 2018

  • Enbrel revenue outside US and Canadian markets fell 14% YoY (year-over-year) to $506 million.
  • BeneFix revenue fell 2% YoY to $147 million due to international sales falling to $79 million, offset by US sales rising to $68 million.
  • Celebrex revenue fell 17% YoY to $145 million due to US sales falling to $16 million and international sales falling to $129 million.
  • EpiPen, Mylan’s (MYL) blockbuster drug, contains a drug manufactured by Pfizer. Pfizer’s EpiPen revenue fell 36% YoY to $52 million due to US and international sales falling.
  • Inylta revenue fell 13% YoY to $74 million due to US sales falling to $28 million and international sales falling to $46 million.
  • Viagra revenue fell 45% YoY to $187 million due to US sales falling to $88 million, offset by international sales rising to $99 million.
  • Zyvox revenue fell 11% YoY to $68 million due to US sales falling to $6 million and international sales falling to $63 million.

The iShares Evolved US Innovative Healthcare ETF (IEIH) invests 6.4% of its holdings in Pfizer, 5.6% in AbbVie (ABBV), 5.6% in Eli Lilly (LLY), and 5.1% in Biogen (BIIB).

More From Market Realist